Shapiro Galina, Wong Andrew W, Bez Maxim, Yang Fang, Tam Sarah, Even Lisa, Sheyn Dmitriy, Ben-David Shiran, Tawackoli Wafa, Pelled Gadi, Ferrara Katherine W, Gazit Dan
Skeletal Biotech Laboratory, The Hebrew University-Hadassah Faculty of Dental Medicine, Ein Kerem, Jerusalem 91120, Israel.
University of California, Davis, Department of Biomedical Engineering, 451 Health Sciences Drive, Davis, CA 95616, USA.
J Control Release. 2016 Feb 10;223:157-164. doi: 10.1016/j.jconrel.2015.12.001. Epub 2015 Dec 10.
More than 1800 gene therapy clinical trials worldwide have targeted a wide range of conditions including cancer, cardiovascular diseases, and monogenic diseases. Biological (i.e. viral), chemical, and physical approaches have been developed to deliver nucleic acids into cells. Although viral vectors offer the greatest efficiency, they also raise major safety concerns including carcinogenesis and immunogenicity. The goal of microbubble-mediated sonoporation is to enhance the uptake of drugs and nucleic acids. Insonation of microbubbles is thought to facilitate two mechanisms for enhanced uptake: first, deflection of the cell membrane inducing endocytotic uptake, and second, microbubble jetting inducing the formation of pores in the cell membrane. We hypothesized that ultrasound could be used to guide local microbubble-enhanced sonoporation of plasmid DNA. With the aim of optimizing delivery efficiency, we used nonlinear ultrasound and bioluminescence imaging to optimize the acoustic pressure, microbubble concentration, treatment duration, DNA dosage, and number of treatments required for in vivo Luciferase gene expression in a mouse thigh muscle model. We found that mice injected with 50μg luciferase plasmid DNA and 5×10(5) microbubbles followed by ultrasound treatment at 1.4MHz, 200kPa, 100-cycle pulse length, and 540 Hz pulse repetition frequency (PRF) for 2min exhibited superior transgene expression compared to all other treatment groups. The bioluminescent signal measured for these mice on Day 4 post-treatment was 100-fold higher (p<0.0001, n=5 or 6) than the signals for controls treated with DNA injection alone, DNA and microbubble injection, or DNA injection and ultrasound treatment. Our results indicate that these conditions result in efficient gene delivery and prolonged gene expression (up to 21days) with no evidence of tissue damage or off-target delivery. We believe that these promising results bear great promise for the development of microbubble-enhanced sonoporation-induced gene therapies.
全球范围内超过1800项基因治疗临床试验针对多种病症,包括癌症、心血管疾病和单基因疾病。已开发出生物(即病毒)、化学和物理方法将核酸递送至细胞。尽管病毒载体具有最高的效率,但它们也引发了重大的安全问题,包括致癌作用和免疫原性。微泡介导的声孔效应的目标是增强药物和核酸的摄取。微泡的超声作用被认为有助于两种增强摄取的机制:第一,细胞膜的偏转诱导内吞摄取;第二,微泡喷射诱导细胞膜上形成孔道。我们假设超声可用于引导质粒DNA的局部微泡增强声孔效应。为了优化递送效率,我们使用非线性超声和生物发光成像来优化声压、微泡浓度、治疗持续时间、DNA剂量以及在小鼠大腿肌肉模型中进行体内荧光素酶基因表达所需的治疗次数。我们发现,与所有其他治疗组相比,注射50μg荧光素酶质粒DNA和5×10⁵个微泡,随后在1.4MHz、200kPa、100周期脉冲长度和540Hz脉冲重复频率(PRF)下进行2分钟超声治疗的小鼠表现出更高的转基因表达。在治疗后第4天,这些小鼠测得的生物发光信号比仅接受DNA注射、DNA和微泡注射或DNA注射及超声治疗的对照组信号高100倍(p<0.0001,n = 5或6)。我们的结果表明,这些条件可实现高效的基因递送和延长的基因表达(长达21天),且没有组织损伤或脱靶递送的证据。我们相信这些有前景的结果为微泡增强声孔效应诱导的基因治疗的发展带来了巨大希望。